Gene · 8784
Papers4,557
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,557
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. | Br J Cancer | 2024 | 37945751 | PubTator, text mining | PubMed |
| Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. | Leukemia | 2024 | 37919606 | PubTator, text mining | PubMed |
| Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. | Cancer Discov | 2024 | 37861461 | PubTator, text mining | PubMed |
| Peripheral helper T cells, mavericks of peripheral immune responses. | Int Immunol | 2024 | 37788648 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing in juvenile idiopathic arthritis. | Genes Dis | 2024 | 37692495 | PubTator, text mining | PubMed |
| Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics. | Front Immunol | 2023 | 38299154 | PubTator, text mining | PubMed |
| Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development. | Dev Reprod | 2023 | 38292233 | PubTator, text mining | PubMed |
| Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity. | Front Immunol | 2023 | 38283365 | PubTator, text mining | PubMed |
| Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review. | Front Immunol | 2023 | 38283354 | PubTator, text mining | PubMed |
| Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model. | Vaccines (Basel) | 2023 | 38276666 | PubTator, text mining | PubMed |
| Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response. | Curr Oncol | 2023 | 38275827 | PubTator, text mining | PubMed |
| Treg in inborn errors of immunity: gaps, knowns and future perspectives. | Front Immunol | 2023 | 38259469 | PubTator, text mining | PubMed |
| Heterogeneity and subtypes of CD4+ regulatory T cells: implications for tumor therapy. | Front Immunol | 2023 | 38250084 | PubTator, text mining | PubMed |
| Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity? | J Pers Med | 2023 | 38248751 | PubTator, text mining | PubMed |
Diverse and Synergistic Actions of Phytochemicals in a Plant-Based Multivitamin/Mineral Supplement against Oxidative Stress and Inflammation in Healthy Individuals: A Systems Biology Approach Based on a Randomized Clinical Trial. | Antioxidants (Basel) | 2023 | 38247460 | PubTator, text mining | PubMed |
| Spatial profiling of the placental chorioamniotic membranes reveals upregulation of immune checkpoint proteins during Group B Streptococcus infection in a nonhuman primate model. | Front Cell Infect Microbiol | 2023 | 38239507 | PubTator, text mining | PubMed |
| Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes. | Explor Target Antitumor Ther | 2023 | 38213535 | PubTator, text mining | PubMed |
| Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model. | Front Immunol | 2023 | 38213329 | PubTator, text mining | PubMed |
| Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. | Cancers (Basel) | 2023 | 38201551 | PubTator, text mining | PubMed |
| Pneumonia in the first week after polytrauma is associated with reduced blood levels of soluble herpes virus entry mediator. | Front Immunol | 2023 | 38187375 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8784/papers?page=11